

Judith R Kroep

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8459930/publications.pdf>

Version: 2024-02-01

157
papers

8,271
citations

41344

49
h-index

51608

86
g-index

159
all docs

159
docs citations

159
times ranked

12583
citing authors

#	ARTICLE	IF	CITATIONS
1	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	27.8	637
2	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 901-908.	10.7	487
3	Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?. <i>European Journal of Cancer</i> , 2011, 47, 2431-2445.	2.8	386
4	Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment. <i>Cancer Research</i> , 2013, 73, 2480-2492.	0.9	285
5	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012, 118, 1649-1655.	4.1	222
6	Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. <i>Gynecologic Oncology</i> , 2014, 135, 231-238.	1.4	200
7	The Clinical Approach Toward Giant Cell Tumor of Bone. <i>Oncologist</i> , 2014, 19, 550-561.	3.7	199
8	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015, 26, 1280-1291.	1.2	177
9	Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. <i>Nature Communications</i> , 2020, 11, 3083.	12.8	173
10	The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. <i>BMC Cancer</i> , 2015, 15, 652.	2.6	170
11	Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. <i>Science Translational Medicine</i> , 2016, 8, 334ra52.	12.4	164
12	First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study. <i>Annals of Oncology</i> , 2011, 22, 207-214.	1.2	163
13	Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1271-1286.	4.2	161
14	Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 37, 422-30.	7.7	160
15	Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 371-6.	4.1	145
16	A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon- γ in patients with recurrent epithelial ovarian cancer. <i>Annals of Oncology</i> , 2015, 26, 2141-2149.	1.2	144
17	Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 2190-2190.	1.6	141
18	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). <i>Journal of the National Cancer Institute</i> , 2018, 110, 40-48.	6.3	138

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). <i>Breast Cancer Research and Treatment</i> , 2013, 139, 371-379.	2.5	127
20	Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. <i>BMC Cancer</i> , 2010, 10, 462.	2.6	119
21	Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1502-1511.	10.7	119
22	Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukoencephalopathy syndrome. <i>Annals of Oncology</i> , 2007, 18, 1745-1747.	1.2	118
23	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	1.6	116
24	The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review. <i>Cancer Treatment Reviews</i> , 2018, 62, 18-28.	7.7	103
25	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	83
26	Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. <i>Annals of Oncology</i> , 1999, 10, 441-448.	1.2	81
27	Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study. <i>Lancet Oncology</i> , The, 2014, 15, 722-729.	10.7	81
28	Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. <i>British Journal of Cancer</i> , 2000, 83, 1069-1076.	6.4	80
29	Development of a Decision Aid about fertility preservation for women with breast cancer in the Netherlands. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2013, 34, 170-178.	2.1	77
30	Effects of short-term fasting on cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 209.	8.6	76
31	Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. <i>European Journal of Cancer</i> , 2010, 46, 3016-3021.	2.8	74
32	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , 2019, 154, 441-448.	1.4	74
33	Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. <i>Molecular Imaging and Biology</i> , 2003, 5, 337-346.	2.6	73
34	Multicenter Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) Identifies Proteomic Differences in Breast-Cancer-Associated Stroma. <i>Journal of Proteome Research</i> , 2014, 13, 4730-4738.	3.7	72
35	The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012, 94-B, 882-888.	3.4	69
36	Adherence and patients' experiences with the use of oral anticancer agents. <i>Acta Oncologica</i> , 2014, 53, 259-267.	1.8	68

#	ARTICLE	IF	CITATIONS
37	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	10.7	68
38	Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – A phase II trial. <i>European Journal of Cancer</i> , 2014, 50, 2190-2200.	2.8	67
39	The prognostic role of TGF- β 2 signaling pathway in breast cancer patients. <i>Annals of Oncology</i> , 2013, 24, 384-390.	1.2	65
40	Gemcitabine–cisplatin: A schedule finding study. <i>Annals of Oncology</i> , 1999, 10, 1503-1510.	1.2	64
41	The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 190-203.	1.7	64
42	Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. <i>Cancer Treatment Reviews</i> , 2018, 62, 74-90.	7.7	61
43	A multidisciplinary approach to giant cell tumors of tendon sheath and synovium – A critical appraisal of literature and treatment proposal. <i>Journal of Surgical Oncology</i> , 2013, 107, 433-445.	1.7	60
44	Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. <i>Annals of Oncology</i> , 2013, 24, 931-937.	1.2	58
45	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. <i>Oncotarget</i> , 2015, 6, 32228-32243.	1.8	58
46	Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2000, 1474, 5-12.	2.4	54
47	Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer. <i>Current Pharmaceutical Design</i> , 2012, 18, 3816-3827.	1.9	54
48	Illness Perceptions in Women with Breast Cancer – a Systematic Literature Review. <i>Current Breast Cancer Reports</i> , 2015, 7, 117-126.	1.0	53
49	Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making. <i>European Journal of Cancer</i> , 2016, 66, 55-66.	2.8	53
50	Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2014, 40, 86-92.	7.7	52
51	Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. <i>Breast Cancer Research</i> , 2012, 14, R93.	5.0	50
52	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 821-827.	4.1	49
53	CDK4/6 inhibition in early and metastatic breast cancer: A review. <i>Cancer Treatment Reviews</i> , 2017, 60, 130-138.	7.7	49
54	Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1211-1220.	10.7	45

#	ARTICLE	IF	CITATIONS
55	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1255-1268.	3.8	45
56	Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 680-689.	4.1	44
57	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2132-2145.	3.8	41
58	Illness Perceptions and Quality of Life in Japanese and Dutch Women with Breast Cancer. <i>Journal of Psychosocial Oncology</i> , 2013, 31, 83-102.	1.2	40
59	Disclosing the Uncertainty Associated with Prognostic Estimates in Breast Cancer. <i>Medical Decision Making</i> , 2017, 37, 179-192.	2.4	39
60	The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival. <i>Oncoimmunology</i> , 2018, 7, e1465166.	4.6	36
61	Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence. <i>Cancer Treatment Reviews</i> , 2015, 41, 271-276.	7.7	34
62	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). <i>Annals of Oncology</i> , 2014, 25, 998-1004.	1.2	33
63	Optical Mammography Using Diffuse Optical Spectroscopy for Monitoring Tumor Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 577-584.	7.0	32
64	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	2.2	31
65	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102973.	4.4	31
66	Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. <i>Annals of Oncology</i> , 2004, 15, 230-235.	1.2	30
67	Insulin-like growth factor 1 receptor expression and IGF1R 3129G>T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , 2016, 18, 3.	5.0	30
68	The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. <i>Cancers</i> , 2020, 12, 2805.	3.7	30
69	Vitamin D (25-OH D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01). <i>Breast</i> , 2016, 25, 69-74.	2.2	29
70	Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial. <i>Molecular Oncology</i> , 2015, 9, 1120-1128.	4.6	28
71	Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. <i>Oncoimmunology</i> , 2014, 3, e962397.	4.6	27
72	Fertility-sparing surgery of cervical cancer >2 cm (International Federation of Gynecology and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 <i>Gynecological Cancer</i> , 2020, 30, 115-121.	2.5	27

#	ARTICLE	IF	CITATIONS
73	Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013â€”14) trial. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 741-758.	2.5	27
74	Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. <i>JAMA Network Open</i> , 2021, 4, e2113180.	5.9	27
75	Diflomotecan, a promising homocamptothecin for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 69-75.	4.1	26
76	Importance of patient reported outcome measures versus clinical outcomes for breast cancer patients evaluation on quality of care. <i>Breast</i> , 2016, 27, 62-68.	2.2	26
77	Cross-cultural comparison of breast cancer patientsâ€™ Quality of Life in the Netherlands and Japan. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 459-471.	2.5	26
78	Breast cancer specialistsâ€™ views on and use of risk prediction models in clinical practice: A mixed methods approach. <i>Acta Oncologica</i> , 2015, 54, 361-367.	1.8	24
79	Tumorâ€”stroma ratio is associated with <scp>Millerâ€”Payne</scp> score and pathological response to neoadjuvant chemotherapy in <scp>HER2</scp>-negative early breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 1181-1188.	5.1	24
80	The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks. <i>Cancers</i> , 2021, 13, 2994.	3.7	23
81	Experimental drugs and drug combinations in pancreatic cancer. <i>Annals of Oncology</i> , 1999, 10, S234-S238.	1.2	22
82	Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. <i>British Journal of Cancer</i> , 2020, 122, 1453-1460.	6.4	22
83	Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer. <i>Oncotarget</i> , 2017, 8, 15610-15620.	1.8	21
84	Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cyler PCR in relation to enzyme activity and gemcitabine sensitivity. <i>Cancer Letters</i> , 2004, 213, 173-179.	7.2	20
85	Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3273-3281.	1.6	20
86	Extraâ€”abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. <i>Journal of Cutaneous Pathology</i> , 2009, 36, 565-569.	1.3	19
87	Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	19
88	Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. <i>Annals of Oncology</i> , 2004, 15, 484-488.	1.2	18
89	Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 247-252.	2.5	18
90	Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 600-611.	2.8	18

#	ARTICLE	IF	CITATIONS
91	Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 257-265.	2.5	18
92	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. <i>JAMA Oncology</i> , 2020, 6, 528.	7.1	17
93	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2000-2000.	1.6	17
94	Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research and Treatment</i> , 2015, 149, 461-466.	2.5	16
95	Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial. <i>Oncologist</i> , 2019, 24, 889-e421.	3.7	16
96	Randomised study of tegafurâ€“uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer â€” TLC study. <i>Journal of Geriatric Oncology</i> , 2015, 6, 307-315.	1.0	15
97	Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma. <i>Cancers</i> , 2020, 12, 3568.	3.7	15
98	No evidence of gemcitabine accumulation during weekly administration. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 843-849.	1.9	14
99	Pharmacology of the paclitaxelâ€“cisplatin, gemcitabineâ€“cisplatin, and paclitaxelâ€“gemcitabine combinations in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 509-516.	2.3	14
100	Psychosocial determinants of adherence with oral anticancer treatment: â€“we donâ€™t need no educationâ€™. <i>Acta Oncologica</i> , 2021, 60, 87-95.	1.8	14
101	Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e704-e711.	4.6	14
102	Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 605-615.	2.5	13
103	The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer. <i>Current Pharmaceutical Design</i> , 2012, 18, 3775-3783.	1.9	12
104	Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2963-2970.	2.0	12
105	Quantitative assessment of lymph vascular space invasion (LVSI) provides important prognostic information in node-negative breast cancer. <i>Annals of Oncology</i> , 2013, 24, 2994-2998.	1.2	11
106	The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 361-370.	2.5	11
107	Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 65-74.	2.5	11
108	Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1141-1147.	2.5	11

#	ARTICLE	IF	CITATIONS
109	Metastatic breast cancer in older patients: A longitudinal assessment of geriatric outcomes. <i>Journal of Geriatric Oncology</i> , 2020, 11, 969-975.	1.0	11
110	Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 407.e1-407.e16.	1.3	11
111	Editorial: Advances in Epithelial Ovarian Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 3735-3740.	1.9	10
112	Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1879-1887.	2.5	10
113	Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 27-36.	2.5	10
114	Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 567-577.	2.5	10
115	Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. <i>International Journal of Cancer</i> , 2019, 145, 1325-1333.	5.1	8
116	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10516-10516.	1.6	8
117	Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity. <i>Cancers</i> , 2022, 14, 1390.	3.7	8
118	We're in this together: Patients, caregivers and health care providers' illness perceptions about non-small-cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2015, 90, 575-581.	2.0	7
119	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial. <i>Cancer</i> , 2016, 122, 2961-2970.	4.1	7
120	Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. <i>European Journal of Cancer</i> , 2018, 95, 59-67.	2.8	7
121	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. <i>International Journal of Cancer</i> , 2019, 145, 274-283.	5.1	7
122	PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System. <i>Cancers</i> , 2021, 13, 5179.	3.7	7
123	Feasibility of tailored follow-up for patients with early breast cancer. <i>Breast</i> , 2014, 23, 852-858.	2.2	6
124	Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , 2019, 21, 97.	5.0	6
125	Illness Perceptions and Quality of Life in Patients with Non-Small-Cell Lung Cancer: A 3-Month Follow-Up Pilot Study. <i>Patient Related Outcome Measures</i> , 2020, Volume 11, 67-71.	1.2	6
126	Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5525-5525.	1.6	6

#	ARTICLE	IF	CITATIONS
127	Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies. <i>Oncotarget</i> , 2017, 8, 46557-46564.	1.8	6
128	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2934-2945.	1.6	6
129	Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 413-420.	2.5	5
130	Lifetime Transfusion Burden and Transfusion-Related Iron Overload in Adult Survivors of Solid Malignancies. <i>Oncologist</i> , 2020, 25, e341-e350.	3.7	5
131	Using a quality of life (QoL)-monitor: preliminary results of a randomized trial in Dutch patients with early breast cancer. <i>Quality of Life Research</i> , 2020, 29, 2961-2975.	3.1	5
132	The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. <i>Scientific Reports</i> , 2021, 11, 3249.	3.3	5
133	Giving A Face to Chemotherapy-Induced Alopecia: A Feasibility Study on Drawings by Patients. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2020, 7, 218-224.	1.6	5
134	Symptoms of anxiety but not depression before start of taxane-based chemotherapy are associated with peripheral neuropathy: a multicenter study in women with breast cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 6947-6953.	2.2	5
135	Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 675-685.	2.5	4
136	Case series, Chemotherapy-induced cardiomyopathy: mind the family history!. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab333.	0.6	4
137	Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?. <i>Journal of Clinical Medicine</i> , 2013, 2, 188-200.	2.4	3
138	Clinical Activity of Gemcitabine as a Single Agent and in Combination. , 2006, , 253-288.		3
139	Quantitative Real Time PCR of Deoxycytidine Kinase mRNA by Light Cycler PCR; in Relation to Enzyme Activity. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1347-1350.	1.1	2
140	Primary Ewing sarcoma of the iris. <i>Lancet, The</i> , 2014, 383, 256.	13.7	2
141	Effects of controlled ovarian stimulation on toxicity of TAC chemotherapy in early breast cancer patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 3931-3935.	1.9	2
142	Validity and Reliability of the Japanese Version of the 10-Item Perceived Efficacy in Patient-Physician Interactions (PEPPI-10) Scale in Breast Cancer Outpatients. <i>Tohoku Journal of Experimental Medicine</i> , 2019, 249, 121-126.	1.2	2
143	Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making. <i>Gynecologic Oncology</i> , 2021, 161, 727-733.	1.4	2
144	NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)-A Dutch Breast Cancer Trialists' Group (BOOG) study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1028-1028.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Early identification of non-responding locally advanced breast tumors receiving neoadjuvant chemotherapy. , 2015, , .		1
146	The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).. Journal of Clinical Oncology, 2021, 39, 524-524.	1.6	1
147	Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X).. Journal of Clinical Oncology, 2013, 31, 1072-1072.	1.6	1
148	A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study.. Journal of Clinical Oncology, 2013, 31, e22106-e22106.	1.6	1
149	Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.. Journal of Clinical Oncology, 2017, 35, 523-523.	1.6	1
150	Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia " a randomized controlled trial. Supportive Care in Cancer, 2022, , .	2.2	1
151	In Reply. Oncologist, 2014, 19, 1208-1208.	3.7	0
152	RE: Serum vit D levels and response to molecular subtypes in breast cancer. Breast, 2016, 27, 186.	2.2	0
153	ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi5-vi5.	1.2	0
154	Perceptions of Japanese and Dutch women with early breast cancer about monitoring their quality of life. Journal of Psychosocial Oncology, 2021, , 1-14.	1.2	0
155	Quality of life and its associations with illness perceptions over a 3"month follow"up period in patients with non"small cell lung cancer: A prospective longitudinal study. World Academy of Sciences Journal, 2021, 3, .	0.6	0
156	Assessment and management of bone health in women treated with adjuvant anastrozole in the DATA study.. Journal of Clinical Oncology, 2018, 36, 534-534.	1.6	0
157	Effects of a Self-Monitoring Quality of Life Intervention in Outpatients with Breast Cancer: A Preliminary Report of A Randomized Controlled Trial. Asian Pacific Journal of Cancer Prevention, 2022, 23, 53-59.	1.2	0